Metagenomi Therapeutics Inc
(MGX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2023 | 12-2022 | 12-2021 | |
| Sales | 8,657 | 0 | 0 |
| Gross Profit | 8,657 | N/A | N/A |
| Operating Expenses | 26,595 | 0 | 0 |
| Operating Income | -17,938 | N/A | N/A |
| Other Income | 4,002 | 0 | 0 |
| Pre-tax Income | -13,936 | 0 | 0 |
| Income Tax | 2,197 | N/A | N/A |
| Net Income Continuous | -16,133 | N/A | N/A |
| Net Income | $-16,133 | $N/A | $N/A |
| EPS Basic Total Ops | -4.74 | N/A | N/A |
| EPS Basic Continuous Ops | -4.74 | N/A | N/A |
| EPS Diluted Total Ops | -4.74 | N/A | N/A |
| EPS Diluted Continuous Ops | -4.74 | N/A | N/A |
| EBITDA(a) | $-19,330 | $N/A | $N/A |